Clinical Trials

30 enrolled

Nasopharyngeal Carcinoma

NCT07070479 2025-09-18

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

208 enrolled

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT06912711 2025-05-21

TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

70 enrolled

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma

NCT04456322 2025-05-14

Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

381 enrolled

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

NCT04223024 2025-03-05

Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma

246 enrolled

Nasopharyngeal Carcinoma

NCT03025958 2024-05-06

Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 2 Completed

30 enrolled

Nasopharyngeal Carcinoma

NCT06259721 2024-03-07

Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

22 enrolled

Nasopharyngeal Carcinoma

NCT03708822 2024-01-18

Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

48 enrolled

Nasopharyngeal Carcinoma

NCT06026878 2023-09-07

GNT Induction Treatment in Locally Advanced NPC

Phase 3 Recruiting

228 enrolled

Nasopharyngeal Carcinoma

NCT05772208 2023-03-16

Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

Phase 3 Recruiting

459 enrolled

Nasopharyngeal Carcinoma

NCT05717790 2023-02-08

Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma

Phase NA Recruiting

288 enrolled

Nasopharyngeal Carcinoma

NCT03837808 2022-11-07

Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma

Phase 3 Unknown

384 enrolled

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms

NCT04508816 2022-04-04

Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Phase 2 Completed

45 enrolled

Nasopharyngeal Carcinoma

NCT03915132 2021-01-29

Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma

47 enrolled

Nasopharyngeal Carcinoma

NCT03557112 2018-11-02

By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC

180 enrolled

Nasopharyngeal Carcinoma

NCT03666221 2018-09-11

Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

67 enrolled

Nasopharyngeal Carcinoma, Recurrence

NCT01616849 2015-09-22

Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma

Phase 2 Completed

39 enrolled

Nasopharyngeal Carcinoma

NCT02293356 2015-08-19

Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma

Phase 4 Unknown

2,000 enrolled